Rolf Brekken

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. pmc SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-β1 activity
    Lee B Rivera
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    J Cell Biol 193:1305-19. 2011
  2. pmc Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer
    Christina L Roland
    Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
    PLoS ONE 4:e7669. 2009
  3. pmc Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation
    Shanna A Arnold
    Division of Surgical Oncology, Department of Surgery and Pharmacology, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
    PLoS ONE 7:e31384. 2012
  4. pmc r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction
    Laura A Sullivan
    Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
    PLoS ONE 5:e12031. 2010
  5. pmc Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium
    Michael T Dellinger
    Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
    PLoS ONE 6:e28947. 2011
  6. ncbi request reprint PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer
    Katherine T Ostapoff
    Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75390, USA
    Mol Cancer Ther 12:1190-201. 2013
  7. pmc BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer
    Bercin Kutluk Cenik
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Mol Cancer Ther 12:992-1001. 2013
  8. pmc SPARC: a matricellular regulator of tumorigenesis
    Shanna A Arnold
    Hamon Center for Therapeutic Oncology Research, Division of Surgical Oncology and Departments of Surgery and Pharmacology, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75390 8593 USA
    J Cell Commun Signal 3:255-73. 2009
  9. pmc Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer
    Niranjan Awasthi
    Division of Surgical Oncology, Department of Surgery, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    BMC Cancer 11:15. 2011
  10. pmc GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer
    Kristi D Lynn
    Division of Surgical Oncology, Department of Surgery, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 76259, USA
    BMC Cancer 10:397. 2010

Collaborators

  • Kristi D Lynn
  • Li Zhang
  • Stefan Hinz
  • Roderich E Schwarz
  • Keith Dredge
  • Niranjan Awasthi
  • Sean P Dineen
  • Thomas J Kodadek
  • Shanna A Arnold
  • Bercin Kutluk Cenik
  • Katherine T Ostapoff
  • Lee B Rivera
  • Laura A Sullivan
  • Jason E Toombs
  • Christina L Roland
  • Xinyu Li
  • Jagmohan Hooda
  • Michael T Dellinger
  • Juliet G Carbon
  • Yi Hung Ou
  • Jakub Hanus
  • Michael Dellinger
  • Daniela Cadinu
  • Thai M Cao
  • Chastain Anderson
  • Shusheng Wang
  • Hongmei Zhang
  • Ajit Shah
  • David E Gerber
  • Qinbo Zhou
  • Md Maksudul Alam
  • Amy D Bradshaw
  • Chi Lun Chang
  • Michael Torres
  • Michael A White
  • Rosalyn Ram
  • Seng Lai Tan
  • Ryan Wurz
  • Christina Roland
  • Tzuling Cheng
  • Tony Polverino
  • Etienne Formstecher
  • Andrew Tasker
  • Kyle Schlunegger
  • James A Richardson
  • Mari Nyquist-Andersen
  • Anita Kavlie
  • D Gomika Udugamasooriya

Detail Information

Publications14

  1. pmc SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-β1 activity
    Lee B Rivera
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    J Cell Biol 193:1305-19. 2011
    ..These results demonstrate that SPARC promotes pericyte migration by diminishing TGF-β activity and identify a novel function for endoglin in controlling pericyte behavior...
  2. pmc Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer
    Christina L Roland
    Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
    PLoS ONE 4:e7669. 2009
    ..In addition, we found that changes in serum IL-1beta and IL-6 levels correlated with response to therapy, identifying two possible biomarkers for assessing the effectiveness of anti-VEGF therapy in breast cancer patients...
  3. pmc Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation
    Shanna A Arnold
    Division of Surgical Oncology, Department of Surgery and Pharmacology, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
    PLoS ONE 7:e31384. 2012
    ....
  4. pmc r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction
    Laura A Sullivan
    Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
    PLoS ONE 5:e12031. 2010
    ....
  5. pmc Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium
    Michael T Dellinger
    Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
    PLoS ONE 6:e28947. 2011
    ....
  6. ncbi request reprint PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer
    Katherine T Ostapoff
    Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75390, USA
    Mol Cancer Ther 12:1190-201. 2013
    ..These results highlight the potent antitumor activity of PG545 and support the further exploration of heparanase inhibitors as a potential clinical strategy for the treatment of PDAC...
  7. pmc BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer
    Bercin Kutluk Cenik
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Mol Cancer Ther 12:992-1001. 2013
    ..The absence of EMT induction, which has been implicated in resistance to antiangiogenic therapies, is noteworthy. Together, these results warrant further clinical studies of BIBF 1120...
  8. pmc SPARC: a matricellular regulator of tumorigenesis
    Shanna A Arnold
    Hamon Center for Therapeutic Oncology Research, Division of Surgical Oncology and Departments of Surgery and Pharmacology, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75390 8593 USA
    J Cell Commun Signal 3:255-73. 2009
    ..We aim to provide insight into how a matricellular protein such as SPARC might generate paradoxical, yet relevant, tumor outcomes in order to unify an apparently incongruent collection of scientific literature...
  9. pmc Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer
    Niranjan Awasthi
    Division of Surgical Oncology, Department of Surgery, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    BMC Cancer 11:15. 2011
    ..Smac is an endogenous IAP-antagonist, which renders synthetic Smac mimetics attractive anticancer agents. We evaluated the benefits of combining a Smac mimetic, JP1201 (JP), with conventional chemotherapy agents used for PDAC management...
  10. pmc GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer
    Kristi D Lynn
    Division of Surgical Oncology, Department of Surgery, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 76259, USA
    BMC Cancer 10:397. 2010
    ..We have reported previously the development of an antagonistic VEGFR2 peptoid (GU40C4) that has promising anti-angiogenic activity in vitro and in vivo...
  11. pmc The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer
    Sean P Dineen
    Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical School, Dallas, TX 75390 8593, USA
    BMC Cancer 8:352. 2008
    ..This small protein is based on a human fibronectin domain and has beneficial properties in that it is fully human, stable, and is produced in bacteria. CT-322 binds to and inhibits activation of VEGFR2...
  12. pmc Enhanced heme function and mitochondrial respiration promote the progression of lung cancer cells
    Jagmohan Hooda
    Department of Molecular and Cell Biology, Center for Systems Biology, University of Texas at Dallas, Richardson, Texas, United States of America
    PLoS ONE 8:e63402. 2013
    ..The results show that inhibiting heme and respiratory function can effectively arrest the progression of lung cancer cells. Hence, understanding heme function can positively impact on research in lung cancer biology and therapeutics...
  13. pmc TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation
    Yi Hung Ou
    Department of Cell Biology, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    Mol Cell 41:458-70. 2011
    ..Thus, AKT is a direct TBK1 substrate that connects TBK1 to prosurvival signaling...
  14. pmc Inhibition of multiple pathogenic pathways by histone deacetylase inhibitor SAHA in a corneal alkali-burn injury model
    Xinyu Li
    Department of Ophthalmology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390, United States
    Mol Pharm 10:307-18. 2013
    ..In addition, the potency of SAHA in corneal NV appears to be comparable to the current steroid therapy. SAHA may possess promising therapeutic potential in alkali-burn corneal injury and other inflammatory neovascularization disorders...

Research Grants4